Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) comments on the EMPEROR-Reduced study.

The EMPEROR-Reduced study investigated the safety and efficacy of empagliflozin versus placebo on top of guideline-directed therapy in patients with heart failure with reduced ejection fraction. 

Recorded remotely from Milan, 2020. 

Recording Editor: Natascha Wienand
Editor: Victoria Perroud